Research programme: influenza virus vaccines - Johnson and Johnson/CureVac

Drug Profile

Research programme: influenza virus vaccines - Johnson and Johnson/CureVac

Alternative Names: RNActive® influenza vaccine - Johnson and Johnson/CureVac

Latest Information Update: 16 Aug 2016

Price : $50

At a glance

  • Originator CureVac
  • Developer CureVac; Johnson & Johnson
  • Class Influenza virus vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 03 Oct 2013 Preclinical trials in Influenza virus infections (prevention) in Netherlands (Intradermal)
  • 03 Oct 2013 Preclinical trials in Influenza virus infections (prevention) in Germany (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top